InMode-INMD-Profile-Q12022.ppmt.ppsx
- 1. INMODE PROFILE MAY 2022
- 2. OVERVIEW
- 3. INMODE: WHO WE ARE Leading global provider of innovative, minimally-invasive aesthetic and wellness solutions, with strong brand recognition Broad radiofrequency (“RF”) based portfolio (capital and consumables) providing specialized aesthetic and wellness solutions to plastic surgeons, dermatologists, OB/GYNs, ENTs and ophthalmologists Worldwide regulatory approvals supported by extensive peer-reviewed published clinical data Demonstrated history of profitable growth Global platform with an established direct sales force and extensive distributor network Pipeline to expand medical offerings and adapt proprietary RF technologies to specific applications for plastic and aesthetic surgeons, OB/GYNs, ENTs and ophthalmologists Proven management team with extensive business, scientific and technology experience and expertise 1 2 3 4 5 6 7
- 4. $85.9M Q1-2022 Revenue $113.0-$113.3M Q2-2022 Revenue Guidance $425-$435M Full Year 2022 Revenue Guidance $0.40 Q1-2022 Non-GAAP Diluted Earning per Share Pre-Split 6,100 US Installed Base 12,700 Unit Installed Worldwide 8 Patented Technologies Across 10Product Families 189 Direct Sales Reps Selling in 77 Countries $34.1M Q1-2022 Non-GAAP Net Income INMODE Q1/Q2 2022: BY THE NUMBERS
- 5. INMODE GLOBAL ORGANISATION SELLING IN 77 COUNTRIES 397 employees worldwide, including 189 direct sales reps and 35 person R&D team • 157 person direct sales force in the US and Canada • Logistics Centers in L.A. and Toronto • Distributors by country in South America • Sales and marketing office in Buenos Aires, Argentina • Wholly-owned subsidiaries in Spain, France, UK and Italy • Distributors by country • Middle East countries via UK • Corporate headquarters • R&D and engineering center • Manufacturing and logistics • Corporate finance • Wholly-owned subsidiaries in Israel • Exclusive distributors by country • Sales and marketing office in Hong Kong • Wholly-owned subsidiaries in Australia, India and China AMERICAS EUROPE ISRAEL ASIA
- 7. A ✓ 40 million procedures annually worldwide ✓ Non-invasive, in-office, topical procedures ✓ Typical treatments: hair removal, pigmented lesions, vascular lesions, leg veins, acne ✓ Multiple treatments and limited efficacy ✓ Demographics: 35-60 yrs. old ✓ Looking for comparable results to plastic surgery, but without the shortcomings of full surgery including: ▪ Anaesthesia, downtime, scars ✓ Large population of patients whose skin is not responsive to other skin tightening modalities ✓ Affordable, office-based, out-patient procedure ✓ 2.5 million procedures annually worldwide ✓ Full surgical procedure, with general anaesthesia ✓ Lengthy downtime ✓ High cost ✓ Incisions and scars ✓ Low repeatability, dependent on the doctor’s technique PLASTIC SURGERY THE “TREATMENT GAP” LASER PROCEDURES Significant opportunity for innovative and differentiated minimally-invasive solutions Significant opportunity for InMode to invent and develop minimally-invasive technologies and products for the “Treatment Gap” category ________________________ Source: Medical Insights (2017), ASAPS (2018).
- 8. SOLUTION FOR THE TREATMENT GAP – EVOLUTIONARY PROGRESS Traditional laser companies INMODE
- 9. AESTHETICS INDUSTRY UNDERGOING A PARADIGM SHIFT To: Minimally-Invasive/Ablative Aesthetic Surgery From: Traditional Laser-Based Aesthetics • In-office procedures – mainly hair removal • Non-invasive laser-based procedures • Very limited results that typically require multiple treatments • Patients are seeking new procedures with more significant and longer-lasting results • Growing demand for face and body contouring and not just “laser” rejuvenation or hair removal The new competitive dynamics of the aesthetic surgery industry require a major technological change and a new product portfolio “Treatment Gap” patients are increasingly looking for solutions that address the shortcomings of laser-based aesthetics and the complexity of full surgery
- 10. WHO DO WE SERVE? InMode’s Major Customers In response to physicians’ desires to expand their offering of our aesthetic and wellness office-based procedures, we are developing additional RF solutions targeting their specialties ________________________ Source: Medical Insights (2017), ASAPS (2018) Source: Doctors’ Associations. Note: Estimates based on 2018 data. • 100,000+ surgically-trained physicians in the U.S. and 200,000+ globally • While not all of these physicians focus on aesthetics, many do perform aesthetic procedures • Interested in adding specific medical / wellness procedures related to their area of expertise • “Private pay procedures augment physicians” income – office-based procedures
- 12. DEEP SUBDERMAL FRACTIONAL RF InMode Proprietary Technology Deep Subdermal Fractional RF High-quality results with fewer treatments and shorter downtimes than full aesthetic solutions ✓ Delivers RF energy under the dermis through an array of needle electrodes producing localised heat and small pinpoint coagulation ✓ Can be used for wrinkle treatment, skin tightening, cellulite and acne scars ✓ Heat generated by pins in the sub-dermal tissue promotes both collagen remodelling and fat melting
- 13. MORPHEUS8 BODY - BURST MODALITY ANIMATION
- 14. BEFORE FACE & NECK USING DEEP SUBDERMAL FRACTIONAL RF AFTER “After” results reflect 3 treatments 6 weeks apart ___________________________ Note: These are sample results and may not be indicative of actual results.
- 15. BEFORE BODY USING DEEP SUBDERMAL FRACTIONAL RF AFTER “After” results reflect 2 treatments 4 weeks apart ___________________________ Note: These are sample results and may not be indicative of actual results.
- 16. INMODE’S EXISTING PORTFOLIO OF TECHNOLOGIES Since 2010, InMode has launched multiple innovative product platforms Surgical/RFAL, SARD Hands-Free ‘Traditional’/ Laser Optimas Contoura EmpowerRF Triton Face Women’s Wellness Body Hair Removal BodyFX MiniFX Plus Triton Duo Light Triton Duo Dark FormaV EmbraceRF Face FaceTite Morpheus8 AccuTite Forma Lumecca DiolazeXL Vasculaze Body Platform Application Handpieces FaceTite / NeckTite BodyTite EvolveX Evoke Face Body Cheek Chin BodyTite Tite Tone Morpheus8 Face & Body Morpheus8V Morpheus8 vTone Morpheus8 Body Morpheus8 Morpheus8 Body AccuTite Transform
- 17. DEMONSTRATED HISTORY OF PROFITABLE GROWTH Revenue / Non-GAAP Net Income ($ in millions) Revenue Non-GAAP Net Income • High profitability; 84%-86% gross margins • InMode technologies have sustainable cost advantage • Outsourced manufacturing at fixed cost per unit • Long-term agreements with Medimor and Flex for major parts and sub-systems • Controls procurement of major components and quality assurance • Sustainable tax advantage • Facilities are in highest tax benefit zone within Israel • Starting from 2022, the Company’s corporate tax rate is expected to be between 7.5% to 10%. 23.1 53.5 100.2 156.4 206.1 357.6 65.5 87.3 94.2 110.5 85.9 2.4 10.8 31.9 62.2 89.1 176.3 29.4 43.9 48.1 55.2 34.1 0.0 100.0 200.0 300.0 400.0 2016 2017 2018 2019 2020 2021 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
- 18. INMODE QUALITY MEDICAL MANUFACTURING
- 19. MARKETING TO MEDICAL FOCUS - KEY OPINION LEADERS & LUMINARIES Podium Presentations | Clinical Trials | Publications |Training | Reference Calls | Media Dr. Sherrell Aston Dr. Christine Hamori Dr. Christopher Chia Dr. Erez Dayan Dr. Rod Rohrich
- 20. LEADER IN CLINICAL EXCELLENCE 65+ Peer Reviewed Publications to Date “The mean skin surface area reduction was 25.8% in regions treated with radiofrequency plus SAL at 6 weeks, and increased to 36.4% at 1 year.” - Aesthetic Surgery Journal “RFAL with its safety features presents an alternative to SupL, which has a higher complication rate, risk for contour deformities, and steeper learning curve.” - PRS Global Open “The novel RFAL technology offers immediate skin tightening effect that is stable over time.” - JCDSA “This technology allows precise soft tissue modeling at multiple levels to enhance results over traditional suction-assisted lipecectomy.” - Aesthetic Plastic Surgery
- 21. BUSINESS | CONSUMER | INDUSTRY RECOGNITION